Heart Attack Healing: Anti-Inflammatory Cell Boost | Study
- Los Angeles-A novel scientific approach dramatically increased the production of anti-inflammatory cells, leading to improved heart attack recovery in mice, according to cedars-Sinai Smidt Heart Institute researchers.
- Heart attacks, which occur when reduced blood flow damages the heart muscle, effect over 800,000 Americans annually and remain a leading cause of death.
- Eduardo Marbán, executive director of the Smidt Heart Institute at Cedars-Sinai and the study's senior author, noted that while more than 90% of heart attack patients in the...
Scientists unveil a groundbreaking technique to enhance heart attack healing. This innovative approach, detailed in a recent study, considerably boosts the production of anti-inflammatory cells, leading to improved recovery in mice. the research suggests the potential to repair heart muscle damage in humans and treat various inflammatory conditions. Researchers focused on the crucial role of regulatory T-cells (Tregs) in modulating the immune system after a heart attack, exploring the use of extracellular vesicles. The study highlights the positive impact of BCYRN1 in mice.This research presents a promising avenue for therapies; News Directory 3 keeps you ahead of the curve. Future steps include human trials aiming to help people recover from heart attacks by reducing inflammation and tissue damage.Discover what’s next on the horizon for heart health.
New Technique Boosts Heart Attack Healing in Mice
Updated june 28, 2025
Los Angeles-A novel scientific approach dramatically increased the production of anti-inflammatory cells, leading to improved heart attack recovery in mice, according to cedars-Sinai Smidt Heart Institute researchers. The study, published in the Journal of Clinical Inquiry, suggests the technique could eventually repair heart muscle damage in humans following a heart attack and treat various inflammatory conditions.
Heart attacks, which occur when reduced blood flow damages the heart muscle, effect over 800,000 Americans annually and remain a leading cause of death. The new technique targets a critical challenge: uncontrolled inflammation after a heart attack.
Dr. Eduardo Marbán, executive director of the Smidt Heart Institute at Cedars-Sinai and the study’s senior author, noted that while more than 90% of heart attack patients in the U.S. survive, a meaningful number experience tissue damage due to immune system overreaction.This inflammation weakens the heart and increases heart failure risk.
The researchers focused on boosting the body’s regulatory T-cell (Treg) supply, which helps modulate the immune system.Previous clinical trials extracted, expanded, and re-infused thes cells-a process too slow for acute crises like heart attacks.
The Cedars-Sinai team explored stimulating the body’s own Treg production.Their method, tested in mice, involves infusions of extracellular vesicles overexpressing BCYRN1, an RNA molecule. These vesicles are small sacs containing bioactive substances that circulate in the bloodstream.
Lab experiments on human tissue revealed how BCYRN1 increases Treg cell number and activity. Mice received infusions of BCYRN1-enhanced extracellular vesicles 15 minutes after induced heart attacks.
Results showed that treated mice had more Tregs in their hearts, less cardiac tissue damage, and reduced inflammation compared to untreated mice. Their hearts also maintained better pumping function.The study highlights the important role of BCYRN1 in reducing inflammation and damage from heart attacks, and validates the effectiveness of using extracellular vesicles to deliver these benefits in mice, according to Dr. Ke Liao, project scientist at the Smidt Heart Institute and the study’s first author.
The extracellular vesicles were derived from cardiosphere-derived cells (CDCs), naturally rich in BCYRN1 and developed by Marbán. These progenitor cells originate from human heart tissue.
Although this Smidt Heart Institute study was performed on animals, its findings have the potential to generate new and exciting immunotherapies,” said Dr. Jeffrey A. Golden, director of the burns and Allen Research Institute at Cedars-Sinai. “These therapies could have applications not only for heart attacks but for lupus, organ transplant rejection and other human disorders.
What’s next
Researchers plan to adapt the technique for human trials,possibly leading to new treatments for heart attacks and other inflammatory diseases.Marbán has founder’s equity in Capricor Therapeutics.